Roivant Sciences Ltd (NASDAQ: ROIV)’s stock price has dropped by -1.05 in relation to previous closing price of 11.39. Nevertheless, the company has seen a loss of -2.00% in its stock price over the last five trading days. globenewswire.com reported 2025-06-16 that Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects
Is It Worth Investing in Roivant Sciences Ltd (NASDAQ: ROIV) Right Now?
The stock has a 36-month beta value of 1.16. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ROIV is 419.13M, and at present, short sellers hold a 10.75% of that float. On July 01, 2025, the average trading volume of ROIV was 6.53M shares.
ROIV’s Market Performance
ROIV stock saw a decrease of -2.00% in the past week, with a monthly decline of -0.27% and a quarterly a decrease of 8.57%. The volatility ratio for the week is 2.71%, and the volatility levels for the last 30 days are 3.06% for Roivant Sciences Ltd (ROIV). The simple moving average for the past 20 days is -0.42% for ROIV’s stock, with a 0.45% simple moving average for the past 200 days.
Analysts’ Opinion of ROIV
Many brokerage firms have already submitted their reports for ROIV stocks, with Wolfe Research repeating the rating for ROIV by listing it as a “Outperform.” The predicted price for ROIV in the upcoming period, according to Wolfe Research is $17 based on the research report published on February 15, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ROIV reach a price target of $20. The rating they have provided for ROIV stocks is “Overweight” according to the report published on January 05th, 2024.
Deutsche Bank gave a rating of “Buy” to ROIV, setting the target price at $14 in the report published on December 12th of the previous year.
ROIV Trading at 1.61% from the 50-Day Moving Average
After a stumble in the market that brought ROIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.67% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ROIV starting from Venker Eric, who sale 100,000 shares at the price of $11.45 back on Jun 20 ’25. After this action, Venker Eric now owns 1,462,223 shares of Roivant Sciences Ltd, valued at $1,145,000 using the latest closing price.
Ramaswamy Vivek, the 10% Owner of Roivant Sciences Ltd, sale 577,007 shares at $11.46 during a trade that took place back on Jun 20 ’25, which means that Ramaswamy Vivek is holding 37,284,108 shares at $6,612,500 based on the most recent closing price.
Stock Fundamentals for ROIV
Current profitability levels for the company are sitting at:
- -13.4 for the present operating margin
- 0.92 for the gross margin
The net margin for Roivant Sciences Ltd stands at -2.26. The total capital return value is set at -0.19. Equity return is now at value -8.56, with -7.20 for asset returns.
Based on Roivant Sciences Ltd (ROIV), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -8.38. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -76.22.
Currently, EBITDA for the company is -1.1 billion with net debt to EBITDA at 3.79. When we switch over and look at the enterprise to sales, we see a ratio of 66.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 33.47.
Conclusion
To sum up, Roivant Sciences Ltd (ROIV) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
